中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 42 Issue 4
Apr.  2026
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2026  >  42(4): 866-873

Efficacy of yttrium-90 selective internal radiotherapy in treatment of patients with unresectable hepatocellular carcinoma

DOI: 10.12449/JCH260415
  • 1.

    Department of Hepatology，Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine，Shanghai 201203，China

  • 2.

    First Department of Interventional Radiology，Eastern Hepatobiliary Surgery Hospital，Shanghai 201805，China

Research funding:

National Natural Science Foundation of China (82374251);

2022 National Administration of Traditional Chinese Medicine High-level Key Discipline Construction Project（Traditional Chinese Medicine Hepatobiliary Diseases） (zyyzdxk-2023060);

Shanghai Health Leading Talent Program (2022LJ013)

More Information
  • Corresponding author: YANG Yefa， decentofni@163.com （ORCID： 0000-0002-3160-6641）
  • Received Date: 2025-12-03
  • Accepted Date: 2026-01-30
  • Published Date: 2026-04-25
    Abstract
  •   Objective  To investigate the efficacy of selective internal radiation therapy （SIRT） in patients with unresectable hepatocellular carcinoma， and to provide a reference for the selection of clinical treatment regimens.  Methods  A retrospective analysis was performed for the clinical data of 73 patients with unresectable hepatocellular carcinoma who received yttrium-90 microsphere SIRT in Eastern Hepatobiliary Surgery Hospital from May 1， 2023 to September 1， 2024. According to tumor characteristics， physical status， liver reserve function， laboratory tests， and SIRT treatment strategy， the patients were divided into radiation segmentectomy group with 9 patients， conversion therapy group with 47 patients， and palliative treatment group with 17 patients. Based on the results of postoperative follow-up， modified Response Evaluation Criteria in Solid Tumors were used to assess radiographic images. A one-way analysis of variance was used for comparison of normally distributed continuous data between three groups， and the chi-square test was used for comparison of categorical data between three groups； the Logistic regression model was used to perform the multivariate analysis.  Results  There was a significant difference in postoperative outcome between the radiation segmentectomy group， the conversion therapy group， and the palliative treatment group （χ2 =30.060， P<0.001）. The disease control rate was 100.0% （9/9） in the radiation segmentectomy group， 83.0% （39/47） in the conversion therapy group， and 29.4% （5/17） in the palliative treatment group， with a significant difference between the three groups （χ2 =19.575， P<0.001）， and there was also a significant difference in objective response rate between the three groups （χ2 =17.749， P<0.001）. The multivariate Logistic regression analysis showed that the number of tumors （odds ratio ［OR］=0.085， 95% confidence interval ［CI］： 0.008 — 0.906， P=0.041） and combined targeted immunotherapy （OR=18.808， 95%CI： 1.704 — 207.616， P=0.017） were independent influencing factors for achieving complete response.  Conclusion  The number of tumors is an independent influencing factor for the efficacy of SIRT and is an important basis for selecting different treatment goals. SIRT combined with targeted immunotherapy may achieve better efficacy.

     

    • FullText(HTML)
  • loading
    • References(37)
  • [1]
    European Association for the Study of the Liver. EASL clinical practice guidelines on the management of hepatocellular carcinoma[J]. J Hepatol, 2025, 82( 2): 315- 374. DOI: 10.1016/j.jhep.2024.08.028.
    [2]
    SUNG H, FERLAY J, SIEGEL RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71( 3): 209- 249. DOI: 10.3322/caac.21660.
    [3]
    GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: A systematic analysis for the Global Burden of Disease Study 2015[J]. Lancet, 2016, 388( 10053): 1459- 1544. DOI: 10.1016/S0140-6736(16)31012-1.
    [4]
    WEBER SM, RIBERO D, O'REILLY EM, et al. Intrahepatic cholangiocarcinoma: Expert consensus statement[J]. HPB, 2015, 17( 8): 669- 680. DOI: 10.1111/hpb.12441.
    [5]
    LLOVET JM, DE BAERE T, KULIK L, et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma[J]. Nat Rev Gastroenterol Hepatol, 2021, 18( 5): 293- 313. DOI: 10.1038/s41575-020-00395-0.
    [6]
    LEWANDOWSKI RJ, GABR A, ABOUCHALEH N, et al. Radiation segmentectomy: Potential curative therapy for early hepatocellular carcinoma[J]. Radiology, 2018, 287( 3): 1050- 1058. DOI: 10.1148/radiol.2018171768.
    [7]
    LIU YY, LAI JX, LIU XX. Yttrium 90 microspheres in the management of hepatocellular carcinoma[J]. J Clin Hepatol, 2011, 27( 4): 348- 350. DOI: 10.3969/j.issn.1001-5256.2011.04.005.

    刘允怡, 赖俊雄, 刘晓欣. 钇90微球治疗原发性肝癌[J]. 临床肝胆病杂志, 2011, 27( 4): 348- 350. DOI: 10.3969/j.issn.1001-5256.2011.04.005.
    [8]
    RIAZ A, GATES VL, ATASSI B, et al. Radiation segmentectomy: A novel approach to increase safety and efficacy of radioembolization[J]. Int J Radiat Oncol Biol Phys, 2011, 79( 1): 163- 171. DOI: 10.1016/j.ijrobp.2009.10.062.
    [9]
    RHEE TK, OMARY RA, GATES V, et al. The effect of catheter-directed CT angiography on yttrium-90 radioembolization treatment of hepatocellular carcinoma[J]. J Vasc Interv Radiol, 2005, 16( 8): 1085- 1091. DOI: 10.1097/01.RVI.0000177063.92678.21.
    [10]
    KIM E, SHER A, ABBOUD G, et al. Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma(RASER): A single-centre, single-arm study[J]. Lancet Gastroenterol Hepatol, 2022, 7( 9): 843- 850. DOI: 10.1016/S2468-1253(22)00091-7.
    [11]
    TITANO J, NOOR A, KIM E. Transarterial chemoembolization and radioembolization across Barcelona clinic liver cancer stages[J]. Semin Intervent Radiol, 2017, 34( 2): 109- 115. DOI: 10.1055/s-0037-1602709.
    [12]
    LIVRAGHI T, SOLBIATI L, MELONI MF, et al. Treatment of focal liver tumors with percutaneous radio-frequency ablation: Complications encountered in a multicenter study[J]. Radiology, 2003, 226( 2): 441- 451. DOI: 10.1148/radiol.2262012198.
    [13]
    REIG M, FORNER A, RIMOLA J, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update[J]. J Hepatol, 2022, 76( 3): 681- 693. DOI: 10.1016/j.jhep.2021.11.018.
    [14]
    SALEM R, JOHNSON GE, KIM E, et al. Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: The LEGACY study[J]. Hepatology, 2021, 74( 5): 2342- 2352. DOI: 10.1002/hep.31819.
    [15]
    SALEM R, PADIA SA, TOSKICH BB, et al. Radiation segmentectomy for early hepatocellular carcinoma is curative[J]. J Hepatol, 2025, 82( 6): 1125- 1132. DOI: 10.1016/j.jhep.2025.01.005.
    [16]
    ZHANG H, FU Y, TAN BB, et al. Clinical application and progress of yttrium 90 microsphere selective internal radiation therapy in primary hepatic cancer[J]. Chin J Dig Surg, 2024, 23( 2): 242- 247. DOI: 10.3760/cma.j.cn115610-20231208-00242.

    张辉, 付颖, 谭斌彬, 等. 钇⁃90微球选择性内放射治疗在原发性肝癌中的临床应用及进展[J]. 中华消化外科杂志, 2024, 23( 2): 242- 247. DOI: 10.3760/cma.j.cn115610-20231208-00242.
    [17]
    SANGRO B, SALEM R, KENNEDY A, et al. Radioembolization for hepatocellular carcinoma: A review of the evidence and treatment recommendations[J]. Am J Clin Oncol, 2011, 34( 4): 422- 431. DOI: 10.1097/COC.0b013e3181df0a50.
    [18]
    LEWANDOWSKI RJ, KULIK LM, RIAZ A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: Chemoembolization versus radioembolization[J]. Am J Transplant, 2009, 9( 8): 1920- 1928. DOI: 10.1111/j.1600-6143.2009.02695.x.
    [19]
    BIEDERMAN DM, TITANO JJ, BISHAY VL, et al. Radiation segmentectomy versus TACE combined with microwave ablation for unresectable solitary hepatocellular carcinoma up to 3 cm: A propensity score matching study[J]. Radiology, 2017, 283( 3): 895- 905. DOI: 10.1148/radiol.2016160718.
    [20]
    BIEDERMAN DM, TITANO JJ, KORFF RA, et al. Radiation segmentectomy versus selective chemoembolization in the treatment of early-stage hepatocellular carcinoma[J]. J Vasc Interv Radiol, 2018, 29( 1): 30- 37.e2. DOI: 10.1016/j.jvir.2017.08.026.
    [21]
    SALEM R, LEWANDOWSKI RJ, MULCAHY MF, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: A comprehensive report of long-term outcomes[J]. Gastroenterology, 2010, 138( 1): 52- 64. DOI: 10.1053/j.gastro.2009.09.006.
    [22]
    LENCIONI R, DELLA PINA C, BARTOLOZZI C. Percutaneous image-guided radiofrequency ablation in the therapeutic management of hepatocellular carcinoma[J]. Abdom Imaging, 2005, 30( 4): 401- 408. DOI: 10.1007/s00261-004-0254-8.
    [23]
    POMPILI M, SAVIANO A, DE MATTHAEIS N, et al. Long-term effectiveness of resection and radiofrequency ablation for single hepatocellular carcinoma ≤3 cm. Results of a multicenter Italian survey[J]. J Hepatol, 2013, 59( 1): 89- 97. DOI: 10.1016/j.jhep.2013.03.009.
    [24]
    LIVRAGHI T, MELONI F, DI STASI M, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice?[J]. Hepatology, 2008, 47( 1): 82- 89. DOI: 10.1002/hep.21933.
    [25]
    VOUCHE M, HABIB A, WARD TJ, et al. Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: Multicenter radiology-pathology correlation and survival of radiation segmentectomy[J]. Hepatology, 2014, 60( 1): 192- 201. DOI: 10.1002/hep.27057.
    [26]
    SEROR O, NAULT JC, NAHON P, et al. Is segmental transarterial yttrium 90 radiation a curative option for solitary hepatocellular carcinoma ≤5 cm?[J]. Hepatology, 2015, 61( 1): 406- 407. DOI: 10.1002/hep.27174.
    [27]
    SALEM R, VOUCHE M, HABIB A, et al. Reply: To PMID 24691943[J]. Hepatology, 2015, 61( 1): 407. DOI: 10.1002/hep.27179.
    [28]
    CARDARELLI-LEITE L, CHUNG J, KLASS D, et al. Ablative transarterial radioembolization improves survival in patients with HCC and portal vein tumor thrombus[J]. Cardiovasc Intervent Radiol, 2020, 43( 3): 411- 422. DOI: 10.1007/s00270-019-02404-5.
    [29]
    ZHANG L, FENG XB, HUANG X, et al. Progress in the application of selective internal radiation therapy with yttrium‑90 microsph-eres in the downstaging and conversion treatment of hepatocellular carcinoma before liver transplantation[J]. Chin J Dig Surg, 2024, 23( 12): 1566- 1570. DOI: 10.3760/cma.j.cn115610-20241025-00467.

    张琳, 冯晓彬, 黄鑫, 等. 钇‑90微球选择性内放射治疗在肝癌降期转化移植中的应用进展[J]. 中华消化外科杂志, 2024, 23( 12): 1566- 1570. DOI: 10.3760/cma.j.cn115610-20241025-00467.
    [30]
    SALEM R, GORDON AC, MOULI S, et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma[J]. Gastroenterology, 2016, 151( 6): 1155- 1163.e2. DOI: 10.1053/j.gastro.2016.08.029.
    [31]
    GABR A, POLINENI P, MOULI SK, et al. Neoadjuvant radiation lobectomy as an alternative to portal vein embolization in hepatocellular carcinoma[J]. Semin Nucl Med, 2019, 49( 3): 197- 203. DOI: 10.1053/j.semnuclmed.2019.01.009.
    [32]
    GABA RC, LEWANDOWSKI RJ, KULIK LM, et al. Radiation lobectomy: Preliminary findings of hepatic volumetric response to lobar yttrium-90 radioembolization[J]. Ann Surg Oncol, 2009, 16( 6): 1587- 1596. DOI: 10.1245/s10434-009-0454-0.
    [33]
    TITANO J, VOUTSINAS N, KIM E. The role of radioembolization in bridging and downstaging hepatocellular carcinoma to curative therapy[J]. Semin Nucl Med, 2019, 49( 3): 189- 196. DOI: 10.1053/j.semnuclmed.2019.01.003.
    [34]
    GIRAUD J, CHALOPIN D, BLANC JF, et al. Hepatocellular carcinoma immune landscape and the potential of immunotherapies[J]. Front Immunol, 2021, 12: 655697. DOI: 10.3389/fimmu.2021.655697.
    [35]
    VALERY M, CERVANTES B, SAMAHA R, et al. Immunotherapy and hepatocellular cancer: Where are we now?[J]. Cancers, 2022, 14( 18): 4523. DOI: 10.3390/cancers14184523.
    [36]
    YIN PF, WU K, WANG HZ, et al. Advances in immunotherapy strategy for hepatocellular carcinoma and its application in perioperative period[J/OL]. Chin J Hepat Surg(Electronic Edition), 2026, 15( 1): 21- 27. DOI: 10.3877/cma.j.issn.2095-3232.2026.01.005.

    尹鹏飞, 吴堃, 王槐志, 等. 肝癌免疫治疗策略及其在围手术期中应用进展[J/OL]. 中华肝脏外科手术学电子杂志, 2026, 15( 1): 21- 27. DOI: 10.3877/cma.j.issn.2095-3232.2026.01.005.
    [37]
    SHEN X, ZHAO B. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: Meta-analysis[J]. BMJ, 2018, 362: k3529. DOI: 10.1136/bmj.k3529.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(3)  / Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (46) PDF downloads(10) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return